Author(s): Lin, CC (Lin, Cheng-Chieh); Lai, MM (Lai, Ming-May); Li, TC (Li, Tsai-Chung); Li, CI (Li, Chia-Ing); Liu, CS (Liu, Chiu-Shong); Chen, CC (Chen, Ching-Chu); Wu, MT (Wu, Ming-Tsang)
Title: Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome
Source: DIABETES RESEARCH AND CLINICAL PRACTICE, 85 (1): 24-29 JUL 2009 Language: English
Document Type: Article
Author Keywords: Retinol-binding protein 4; Visfatin; Metabolic syndrome; Insulin resistance KeyWords Plus: COLONY-ENHANCING FACTOR; INSULIN-RESISTANCE; DIABETES- MELLITUS; RETINOL-BINDING-PROTEIN-4; FAT; HYPERINSULINEMIA; IDENTIFICATION;
CRITERIA; OBESITY
Abstract: Background: This study investigates the relationship between serum concentration of RBP4 and visfatin and the metabolic syndrome.
Methods: Patients with metabolic syndrome were studied between October, 2004 and September, 2005. All study subjects were aged 40 and over and lived in Taichung city, Taiwan. The Third Report of the National Cholesterol Education Program's Adult Treatment Panel (ATP III, 2001) was used to define the metabolic syndrome. Serum RBP4 and visfatin levels were measured by enzyme-linked immunosorbent assay.
Results: Serum mean RBP4 levels in subjects who had all five abnormal components of metabolic syndrome (mean +/- SD = 40.8 +/- 18.6) and those who had all components except hyperglycemia (43.5 +/- 23.5) were significantly higher than those in healthy controls (30.3 +/- 14.0 mu g/ml) (p < 0.05). Similar results were not found in serum visfatin levels. Using log- transformed serum RBP4 or visfatin levels as a dependent variable, we found that subjects with all five and four abnormal components of metabolic syndrome had significantly higher mean serum RBP4 levels (p = 0.043 and 0.034, respectively), compared to healthy controls, after adjusting for other covariates. In contrast, similar results were not found in serum visfatin levels.
Conclusion: Metabolic syndrome is significantly associated with serum RBP4, but not serum visfatin. Crown Copyright (C) 2009 Published by Elsevier Ireland Ltd. All rights reserved.
Addresses: [Lin, Cheng-Chieh; Lai, Ming-May; Liu, Chiu-Shong; Wu, Ming-Tsang] China Med Univ Hosp, Dept Family Med, Taichung, Taiwan; [Lin, Cheng-Chieh; Lai, Ming-May; Liu, Chiu- Shong; Chen, Ching-Chu] China Med Univ, Coll Med, Dept Family Med, Taichung, Taiwan;
[Lin, Cheng-Chieh] China Med Univ, Coll Publ Hlth, Sch & Grad Inst Hlth Care Adm, Taichung, Taiwan; [Lin, Cheng-Chieh; Li, Tsai-Chung] Asia Univ, Coll Hlth Sci, Inst Hlth Care Adm, Taichung, Taiwan; [Lin, Cheng-Chieh; Li, Tsai-Chung] China Med Univ, Coll Chinese Med, Grad Inst Biostat, Taichung, Taiwan; [Li, Tsai-Chung] China Med Univ, Ctr Biostat, Taichung,
Taiwan; [Li, Tsai-Chung; Li, Chia-Ing] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Liu, Chiu-Shong] China Med Univ Hosp, Dept Occupat Med, Taichung, Taiwan;
[Chen, Ching-Chu] China Med Univ Hosp, Dept Med, Div Endocrinol & Metab, Taichung, Taiwan; [Wu, Ming-Tsang] Kaohsiung Med Univ, Dept Family Med, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan; [Wu, Ming-Tsang] Kaohsiung Med Univ, Grad Inst Occupat Safety
& Hlth, Kaohsiung, Taiwan
Reprint Address: Wu, MT, Kaohsiung Med Univ, Dept Family Med, Kaohsiung Med Univ Hosp, 100 Shih Chuan 1st Rd, Kaohsiung, Taiwan.
E-mail Address: [email protected] Funding Acknowledgement:
Funding Agency Grant Number
National Science Council of Taiwan 93-2314-B-039-025 94-2314-B-039-024
This study was supported by grants NSC 93-2314-B-039-025 and NSC 94-2314-B-039-024 from the National Science Council of Taiwan. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
Cited References: *NCEP EXP PAN DET, 2002, CIRCULATION, V106, P3143.
ABEL ED, 2001, NATURE, V409, P729.
CARR DB, 2004, DIABETES, V53, P2087.
CHEAL KL, 2004, DIABETES, V53, P1195.
CHEN MP, 2006, J CLIN ENDOCR METAB, V91, P295, DOI 10.1210/jc.2005-1475.
FERRANNINI E, 1991, DIABETOLOGIA, V34, P416.
FUKUHARA A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243.
GAVI S, 2007, J CLIN ENDOCR METAB, V92, P1886.
GRAHAM TE, 2006, NEW ENGL J MED, V354, P2552.
HAIDER DG, 2006, DIABETOLOGIA, V49, P1909, DOI 10.1007/s00125-006-0303-7.
HAIDER DG, 2007, J CLIN ENDOCR METAB, V92, P1168, DOI 10.1210/jc.2006-1839.
HANLEY AJG, 2003, DIABETES, V52, P2740.
KRZYZANOWSKA K, 2006, CLIN SCI, V110, P605, DOI 10.1042/CS20050363.
LEMIEUX I, 2000, CIRCULATION, V102, P179.
PARK YW, 2003, ARCH INTERN MED, V163, P427.
QUADRO L, 1999, EMBO J, V18, P4633.
REAVEN GM, 1988, DIABETES, V37, P1595.
STEPHENS JM, 2006, CURR OPIN LIPIDOL, V17, P128.
YANG Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711.
Cited Reference Count: 19 Times Cited: 1
Publisher: ELSEVIER IRELAND LTD
Publisher Address: ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
ISSN: 0168-8227
DOI: 10.1016/j.diabres.2009.03.016
29-char Source Abbrev.: DIABETES RES CLIN PRACT ISO Source Abbrev.: Diabetes Res. Clin. Pract.
Source Item Page Count: 6
Subject Category: Endocrinology & Metabolism ISI Document Delivery No.: 469PX
